Objective: To evaluate a modified American College of Rheumatology 20 (mACR20) scoring system for patients with rheumatoid arthritis.
Methods: The data were evaluated from one study on patients with methotrexate (MTX)-naive early rheumatoid arthritis (ERA) and another study on patients with DMARD-refractory late rheumatoid arthritis (LRA). For mACR20 scoring, acute-phase reactant measurements were excluded, and 20% improvement from baseline was determined by 2 or 3 of the 4 remaining ACR components.
Results: For full joint counts with data from patients with ERA, marked differences favoured 25 mg etanercept (ETN) over 10 mg ETN by using the unmodified ACR20 (69% v 55%), the mACR203 of 4 (63% v 49%) and the mACR202 of 4 (72% v 58%). An assessment of 28 joints showed similar findings. In the trial on patients with LRA, considerably more patients in both ETN groups achieved a clinical response compared with placebo by using the ACR20, the mACR203 of 4 and the mACR202 of 4, whether using full or 28 joint counts. The mACR203 of 4 and full joint counts with data on patients with ERA showed a marked difference between the MTX and 10 mg ETN groups (63% v 49%), which was not observed with the ACR20.
Conclusion: Patterns of improvement indicated by mACR20 scores were consistent with standard ACR20 scores.
- ACR, American College of Rheumatology
- CRP, C reactive protein
- DAS, Disease Activity Score
- DMARD, disease-modifying antirheumatic drug
- ERA, early rheumatoid arthritis
- ESR, erythrocyte sedimentation rate
- ETN, etanercept
- LRA, late rheumatoid arthritis
- mACR20, modified American College of Rheumatology 20
- MTX, methotrexate
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.